OrthoPediatrics Corp.

As of November 6, 2023, OrthoPediatrics Corp. is considered overvalued and risky due to negative financial metrics and significant underperformance compared to the S&P 500, with a year-to-date return of -13.24% and a 33.10% decline over the past year.

As of June 27, 2025, the technical trend is bearish with moderate strength, driven by bearish daily moving averages and indicators like KST and Dow Theory, despite a mildly bullish MACD on the weekly timeframe.

As of November 6, 2023, OrthoPediatrics Corp. is considered overvalued and risky, with negative financial metrics and a year-to-date stock decline of 11.17%, significantly underperforming the S&P 500's 2.44% gain.

As of June 13, 2025, OrthoPediatrics Corp. is in a bearish trend, indicated by negative MACD readings, bearish moving averages, and consistent bearish signals from KST, suggesting significant weakness in market sentiment.

As of March 2022, the management team of OrthoPediatrics Corp. includes Mr. Terry Schlotterback (Independent Chairman), Mr. Mark Throdahl (CEO), Mr. Fred Hite (CFO and COO), and several directors including Mr. David Pelizzon, Mr. Harald Ruf, Mr. Bernie Berry, Mr. Stephen Burns, and Mr. Bryan Hughes. They oversee the company's operations and strategic direction.

OrthoPediatrics Corp. is a medical device company specializing in products for the pediatric orthopedic market, with recent net sales of $52 million and a market cap of $504.55 million. The company is currently operating at a loss, with a net profit of -$11 million.

As of Jun 18, OrthoPediatrics Corp. has a market capitalization of 504.55 million, with recent net sales of 212.45 million and a net loss of 40.68 million for the latest four quarters. As of December 2024, shareholder's funds were 354.57 million and total assets were 483.70 million.